Alume Biosciences Inc
Last verified 2026-05-16. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $3.1Mattributed |
|---|---|
| Latest round | Funding round, $3.1M, 2025-10-30attributed |
| Founded | 2017 |
| Headquarters | La Jolla, CA |
| Industry | bio |
| Stage | series-b+ |
| Website | alumebiosciences.com |
Alume develops bevonescein (ALM-488), a fluorescent peptide that illuminates nerves intraoperatively. It targets surgeons doing head-and-neck, prostate, and neuro procedures. Differentiator: real-time nerve visualization to reduce iatrogenic nerve injury.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-10-30 | Funding round | $3.1M | undisclosed |
Detected tech stack
LiteSpeed, YouTube, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, PHP, MySQL, wordpress 6.8.5, bootstrap 3.3.5, jquery 3.
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $3.1M | attributed | sec-edgar named as publisher. No document URL on file. |
| Total raised $3.1M | attributed | sec-edgar named as publisher. No document URL on file. |
| Company existence | self-reported | alumebiosciences.com, read 2026-05-16 |
| Description | self-reported | alumebiosciences.com, read 2026-05-16 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $3.1M, 2025-10-30 → Funding round, $3.1M, 2025-10-30, sec-edgar, No document URL on file | Latest round | seed, $3.1M, 2025-10-30 → Funding round, $3.1M, 2025-10-30 | sec-edgar, No document URL on file |
Records begin 2026-09-24. All changes